Delayed diagnosis and clinical course of alpha-mannosidosis: A retrospective study of 25 patients with varying

James H Nurse1, Julia B Hennermann2, Marco A Curiati3

  • 1University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Genetics in Medicine Open
|December 3, 2025
PubMed
Abstract

Insights

Alpha-mannosidosis diagnosis is often delayed, especially in milder cases. Early identification of hearing and learning impairments is crucial for timely intervention in this rare lysosomal storage disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Rare Diseases

Background:

  • Alpha-mannosidosis is an ultrarare lysosomal storage disorder.
  • Significant diagnostic delays occur due to symptom variability and disease rarity.

Purpose of the Study:

  • Evaluate disease manifestation and clinical course in alpha-mannosidosis patients with different disease severities.
  • Identify factors contributing to diagnostic delays in alpha-mannosidosis.

Main Methods:

  • Retrospective chart review of 25 patients diagnosed at age ≥16 years.
  • Patients categorized into mild (n=14) or moderate-severe (n=11) disease groups.
  • Data collected from 11 centers across 7 countries.

Main Results:

  • Longer diagnostic delays observed in mild (26.8 years) vs. moderate-severe (19.7 years) disease.
  • Common initial signs: hearing impairment (mild) and learning/communication disability (moderate-severe).
  • Learning/communication disability was the most frequent key diagnostic sign for both groups; genetic testing confirmed diagnosis in 90%.

Conclusions:

  • Improved diagnostic algorithms are needed for timely alpha-mannosidosis diagnosis and treatment.
  • Early suspicion and testing in patients with hearing, motor, or learning impairments are vital.
  • Continued reassessment of adults awaiting diagnosis is recommended.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
186